Stock Price, News, Quote and Profile of VIVANI MEDICAL INC(NASDAQ:VANI) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

VIVANI MEDICAL INC

NASDAQ:VANI (10/10/2024, 10:54:13 AM)

1.11

-0.01 (-0.89%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryHealth Care Equipment & Supplies

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month-45.89%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap61.34M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Vivani Medical, Inc. develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. The company is headquartered in Alameda, California and currently employs 44 full-time employees. The company went IPO on 2014-11-19. The firm develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. The company is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. The company uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. The company operates through two segments: Biopharm Division and Neuromodulation Division. The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.